Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 12
Submit an article Journal homepage
159
Views
112
CrossRef citations to date
0
Altmetric
Review

Antineoplastic agents from natural sources: achievements and future directions

Gordon M Cragg Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Fairview Center, PO Box B, Frederick, MD 21702-1201, USA. [email protected]
&
David J Newman Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Fairview Center, PO Box B, Frederick, MD 21702-1201, USA. [email protected]
Pages 2783-2797 | Published online: 23 Feb 2005

Bibliography

  • CRAGG GM, NEWMAN DJ, SNADER KM: Natural products in drug discovery and development. J. Nat. Prod. (1997) 60:52–60.
  • •An analysis of the type of chemical source of approved drugs covering the years 1984-1995.
  • NEWMAN DJ, CRAGG GM, SNADER KM: The influence of natural products on drug discovery. Nat. Prod. Rep. (2000) 17:215–234.
  • •A historical review of the influence of natural products on the discovery and development of drugs based upon a natural product pharmacophore.
  • HARTVVELL JL: Plants Used Against Cancer. Quarterman, Lawrence, MA, USA (1982).
  • CRAGG GM, BOYD MR, CARDELLINA II JH, NEWMAN DJ, SNADER KM, MCCLOUD TG: Ethnobotany and drug discovery: the experience of the US National Cancer Institute. In: Ciba Foundation Ethnobotany and the Search for New Drugs' Symposium Vol. 185. Chadwick DJ, Marsh J (Eds.), Wiley & Sons, Chichester, UK (1994):178–196.
  • WANG H-K: Plant-derived anticancer agents currently in clinical use or in clinical trials. IDrugs (1998) 1:92–102.
  • CRAGG GM, SCHEPARTZ SA, SUFFNESS M, GREVER MR:The Taxol supply crisis. New NCI p olicies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod. (1993) 56:1657–1668.
  • KAPOOR LD: CRC Handbook of Ayurvedic Medicinal Plants. CRC Press, Boca Raton, USA (1990).
  • CORTES JE, PAZDUR R: Docetax el. J. Clin. Oncol (1995) 13:2643–2655.
  • POTMEISEL M, PINEDO H: Camptothecins: New AntiCancer Agents. CRC Press, Boca Raton (1995).
  • CRAGG GM, BOYD MR, CARDELLINA II JH et al.: Role of plants in the National Cancer Institute drug discovery and development program. In: Human Medicinal Agents from Plants. Kinghorn AD, Balandrin MF (Eds.), American Chemical Society, Washington, DC, USA (1993):80–95.
  • CHRISTIAN MC, PLUDA JM, HO TC, ARBUCK SG, MURGO AJ, SAUSVILLE EA: Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute. Sem. Oncol. (1997) 24:219–240.
  • •Covers the natural product and synthetic compounds under development at the NCI.
  • PISHA E, CHAI H, LEE I-S et al.: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Med. (1995) 1:1046–1051.
  • MCCONNELL 0, LONGLEY RE, KOEHN FE: The discoveryof marine natural products with therapeutic potential. In: The Discovery of Natural Products with Therapeutic Potential. Gullo VP (Ed.), Butterworth-Heinemann, Boston, USA (1994):109–174.
  • FAULKNER DJ: Marine natural products. Nat. Prod. Reps. (2000) 17:7–55.
  • ••The latest in a comprehensive series of reviews on marinenatural products. The over 800 structures of novel compounds published in 1998 gives one an idea of the structural diversity in the marine environment.
  • OLIVERA BM, WALKER C, CARTIER GE et al.: Speciation of cone snails and interspecific hyper divergence of their venom peptides. Potential evolutionary significance of introns. Ann. NY Acad. Sci. (1999) 870:223–237.
  • ••The discussion of the cone snail toxins and their pharmacol-ogical potential is an excellent introduction to what may best be described as 'Mother Nature's' combinatorial chemistry approach.
  • NEWMAN DJ: Bryostatin-from bryozoan to cancer drug. In: Thyozoans in Space and Time. Proceedings of the 10th International Thyozoology Conference. Gordon DP, Smith AM, Grant-Mackie JA (Eds.), National Institute of Water & Atmospheric Research Ltd, Wellington, NZ (1996):9–17.
  • DAVIDSON SK, HAYGOOD M: Identification of sibling species of the bryozoan Bug-ula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont `Candidatus Endobu-gula sertula'. Biol. Bull. (1999) 196:273–280.
  • ••Identification of a bacterial symbiont that may contain thebiosynthetic machinery for the production of bryostatins.
  • CREWS C, LANE WS, SCHREIBER SL: Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. USA (1996) 93:4316–4319.
  • ••Demonstration of the binding potential of didemnins tointracellular proteins. This work has been extended to show binding to other proteins of import to protein:protein interactions. RINEHART KL: Antitumor compounds from tunicates. Med. Res. Rev. (2000) 20:1–27.
  • CARTE BK: Biomedical potential of marine natural products. Bio-Science (1996) 46:271–286.
  • TAKEBAYASHI Y, POURQUIER P, YOSHIDA A, KOHLHAGEN G, POMMIER Y: Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA (1999) 96:7196–7201.
  • PONCET J: The dolastatins, a family of promising antineoplastic agents. CUIT. Pharm. Des. (1999) 5:139–162.
  • HARRIGAN GG, LUESCH H, YOSHIDA WY, MOORE RE, NAGLE DG, PAUL VJ: Symplostatin 2: A dolastatin 13 analogue from the marine cyanobacterium Symploca hydnoides. J. Nat. Prod. (1999) 62:655–658.
  • •Demonstration that the source of an active material may only be an intermediate in the process, with the true producer being another organism.
  • CRAGG GM, NEWMAN DJ, WEISS RB: Coral reefs, forests and thermal vents: the worldwide exploration of nature for novel antitumor agents. Sem. Oncol. (1997) 24:156–163.
  • BATTERSHILL CN, PAGE MJ, DUCKWORTH AR et al.: Discovery and sustainable supply of marine natural products as drugs, industrial compounds and agro chemicals: Chemical ecology, genetics, aquaculture and cell culture. Mem. Queensland Mus. (1999) 44:76.
  • MUNRO MHG, BLUNT JW, DUMDEI EJ et al.: The discovery and development of marine compounds with pharmaceutical potential. J. Biotech. (1999) 70:15–25.
  • •Covers the areas of in-sea aquaculture and cell culture of marine organisms that produce molecules of pharmacol-ogical importance.
  • TOWLE MJ, SALVATO KA, BUDROW J et al.: Highly potent in vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Proceedings of the 91st Annual Meeting of the American Society for Cancer Research. San Francisco, USA (2000) Abstract 1370.
  • ZHENG W, SELETSKY BM, PALME MH et al.: Synthetic macrocyclic ketone analogs of halichondrin B: Structure-activity relationships. Proceedings of the 91st Annual Meeting of the American Society for Cancer Research. San Francisco, USA (2000):Abstract 1915.
  • HAAR E, KOWALSKI RJ, LIN CM et al.: Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry (1996) 35:243–250.
  • CINEL B, ROBERGE M, BEHRISCH H, VAN OFWEGEN L,CASTRO CB, ANDERSEN RJ: Antimitoticditerpenes from Erythropodium caribaeorum test pharmacophore models for microtubule stabilization. Org. Lett. (2000) 2:257–260.
  • •Example of how using a novel screen will identify materials of interest in a background of highly cytotoxic metabolites.
  • HAMEL E, SACKETT DL, VOURLANIS D, NICOLAOU KC: The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without micro tubule-associated proteins and binding at the polymer tax oid site. Biochemistry (1999) 38:5490–5498.
  • ••An example of how the linkage of an isolated enzyme assaycoupled to combinatorial syntheses around an active natural product skeleton leads to novel agents with increased selectivity.
  • GIANNAKAKOU P, GUSSIO R, NOGALES E et al.: A common pharmacophore for epithilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Nati Acad. Sci. USA (2000) 97:2904–2909.
  • ••An extremely important paper on the derivation of apharmacophore that binds to tubulin and elicits the paclitaxel-like response.
  • PETTIT GR, CICHACZ ZA, GAO F et al.: Isolation andstructure of spongiastatin 1. j Org. Chem. (1993) 58:1302–1304.
  • LACOUR TG, GUO C, BHANDARU S, BOYD MR, FUCHS PL:Interphylal product splicing: The first total syntheses of cephalostatin 1, the North hemisphere of rittera-zinc G and the highly active hybrid analogue, rittero-statin GN1N. J. Am. Chem. Soc. (1998) 120:692–707.
  • PETTIT GR, GADDAMIDI V, HERALD DL et al.: Antineo-plastic agents, 120. Pancratium Littorale. J. Nat. Prod. (1986) 49:995–1002.
  • FOYE WO: Cancer Chemotherapeutic Agents. AmericanChemical Society, Washington, DC, USA (1995).
  • AKINAGA S, SUGIYAMA K, AKIYAMA T: UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Des. (2000) 15:43-52.
  • •A discussion paper on the staurosporin and rebeccamycin classes of natural products and their targets in cells.
  • BOLLAG DM, MCQUENEY PA, ZHU J et al.: Ep o thilon es, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res. (1995) 55:2325–2333.
  • NICOLAOU KC, ROSCHANGAR F, VOURLOUMIS D: Chemical biology of epothilones. Angew. Chem., Int. Ed. Engl. (1998) 37:2014–2045.
  • ••An excellent example of the power of combinatorialsynthesis around a natural product to devise novel, but related, structures with increased selectivity.
  • PANDA D, DELUCA K, WILLIAMS D, JORDAN MA, WILSON L: Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Natl. Acad. Sci. USA (1998) 95:9313–9318.
  • NEWMAN DJ: Mother Nature's pharmacy: A source of novel chemical structures. SIM News (1994) 44:277–283.
  • VENDITTI JM, WESLEY RA, PLOWMAN J: Current NCI preclinical antitumor screening in vivo. Results of tumor panel screening, 1 976–1 982 and future directions. In: Adv. Pharmacol. Chemother. (Vol. 20). Garattini S, Goldin A, Hawking F (Eds.), Academic Press, Orlando, FL, USA (1984):1–20.
  • BOYD MR, PAULL KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. (1995) 34:91–109.
  • PAULL KD, SHOEMAKER RH, HODES L et al.: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPAREalgorithm. J. Natl. Can. Inst. (1989) 81:1088–1089.
  • MAYS TD, MAZAN KD, CRAGG GM, BOYD MR: 'Triang-ular Privity' - a working paradigm for the equitable sharing of benefits from biodiversity research and development. In: Global Genetic Resources: Access, Ownership and Intellectual Property Rights. Hoagland KE, Rossman AY (Eds.), Association of Systematics Collections, Washington, DC, USA (1997):279–298.
  • BAKER JT, BORRIS RP, CARTE B et al.: Natural product drug discovery and development: new perspectives on international collaboration. J. Nat. Prod. (1995) 58:1325-1357. MARSHALL E: Rival genome sequencers celebrate a milestone together. Science (2000) 2 8 8:2294-2295. PENNISI E: Finally, the book of life and instructions for navigating it. Science (2000) 288:2304-2307. ANONYMOUS: New treatment for CML could be model for molecular target-based therapeutics. Cancer Lett. (1999) 25:1–4.
  • CREWS CM, MOHAN R: Small-molecule inhibitors of the cell cycle. Curr. Opin. Chem. Biol. (2000) 4:47–53.
  • SENDEROWICZ A, SAUSVILLE EA: Pr eclinical and clinical development of cyclin-dependent kinase modulators. J. Nat. Can. Inst. (2000) 92:376–387.
  • •A discussion of the clinical candidates that effect changes in the cyclin-dependent kinases.
  • WELLS G, SEATON A, STEVENS MFG: Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine inhibitors with hypervalent iodine reagents. J Merl. Chem. (2000) 43:1550–1562.
  • LEONARD DM: Ras farnesyltransferase: A new therapeutic target. J Merl. Chem. (1997) 40:2971–2990.
  • PAPER DH: Natural products as angiogenesis inhibi-tors. Planta Merl. (1998) 64:686–695.
  • •Natural products as both angiogenic agents and as leads to other structural types.
  • KLOHS WD, HAMBY JM: --Ar.tian,,,-;ogenic agents. Curr. Opin. Biotech. (1999) 10:544–549.
  • HAMBY JM, SHOWALTER HDH: Small molecule inhibi-tors of tumor promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther. (1999) 82:169–193.
  • BROWER V: Tumor angiogenesis-new drugs on the block. Nature Biotech. (1999) 17:963–968.
  • •A discussion of the agents from all sources now in trials as angiogenesis inhibitors.
  • LUTZ RA, KENNISH MJ: Ecology of deep-sea hydrothermal vent communities: A review. Rev. Geophys. (1993) 31:211–242.
  • LUTZ RA, SHANK TM, FORNARI DJ: Rapid growth at deep sea vents. Nature (1994) 371:663–664.
  • BALANDRIN MF, KINGHORN AD, FARNSWORTH NR: Plant-derived natural products in drug discovery and development. An overview. In: Human Medicinal Agents from Plants, Am. Chem. Soc. Symposium Series, No 534. Kinghorn AD, Balandrin MF (Eds.), Am. Chem. Soc., Washington, DC, USA (1993):2–12.
  • YOUNG P: Major microbial diversity initiative recommended. ASM News (1997) 63:417–421.
  • HANDELSMAN J, RONDON MR, BRADY SF, CLARDY J, GOODMAN RM: Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. (1998) 5:R245–R249.
  • ••The use of genetic engineering techniques to recover andclone microbial genomes from crude soil isolates, with the aim of finding novel structures from as yet uncultured microbes. PERSIDIS A: Extremophiles. Nature Biotech. (1998) 16:593-594. PSENNER R, SATTLER B: life at the freezing point. Science (1998) 280:2073-2074. ADAMS MW, KELLY RM: Finding and using hyperther-mophilic enzymes. Trends Biotech. (1998) 16:329-332. HUTCHINSON CR: Microbial polyketide synthases: more and more prolific. Proc. Natl. Acad. Sci. USA (1999) 96:3336-3338. An excellent overview of the current 'state of the art' in combinatorial biosyntheses.
  • GOKHALE RS, TSUJI SY, CANE DE, KHOSLA C: Dissecting and exploiting intermodular communication in polyketide synthases. Science (1999) 284:482–485.
  • RAWLS R: Modular enzymes. Chem. Eng. News (1998) (09 March):29–32.
  • WHITMAN RE, AHLERT J, HOLMAN TR, RUPPEN M, THORSON JS: The gene calC encodes for a non-heme iron metalloprotein responsible for calicheamicin self-resistance in Micromonospora. J. Amer. Chem. Soc. (2000) 122:1556–1557.
  • LIU W, SHEN B: Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globis-porus are clustered with the cagA gene that encodes the C-1027 apoprotein. Antimicrob. Agents Chemother. (2000) 44:382–392.
  • MOLNAR I, SCHUPP T, ONO M et al.: The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium caulosum So ce90. Chem. Biol. (2000) 7:97–109.
  • •Potential for the biochemical biosynthetic production of novel epithilones.
  • SERVICE RF: Drug industry looks to the lab instead ofrainforest and reef. Science (1999) 285:186.
  • WENDER PA, DE BRABANDER J, HARRAN PG et al: Synthesis of the first members of a new class of biologically active bryostatin analogues. j Am. Chem. Soc. (1998) 120:4534–4535.
  • MARTINEZ EJ, OWA T, SCHREIBER SL, COREY EJ: Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinas-cidin 743. Proc. Natl. Acad. Sci. USA (1999) 96:3496–3501.
  • BORMAN S: Four types of natural products that stabilize cell microtubules share structural features. Chem. Eng. News (1999) (26 April):35–36.
  • NICOLAOU KC, WINSSINGER N, VOULOUMIS D et al: Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J Am. Chem. Soc. (1998) 120:10814–10826.
  • NICOLAOU KC, KIM S, PFEFFERKORN J et al: Synthesis and biological activity of sarcodictyins. Angew. Chem. Int. Ed. Engl. (1998) 37:1418–1421.
  • NICOLAOU KC, XU J-Y, KIM S et al: Total synthesis of sarcodictyins A and B. J. Am. Chem. Soc. (1998) 120:8061–8673.
  • •Natural product syntheses from a viewpoint of future combinatorial chemistry production of novel compounds from an active skeleton.
  • NICOLAOU KC, OHSHIMA T, HOSOKAWA S et al: Totalsynthesis of eleutherobin and eleuthosides A and B. J Am. Chem. Soc. (1998) 120:8674–8680.
  • SCHREIBER SL: Chemical genetics resulting from apassion for synthetic organic chemistry. Bioorg. Med. Chem. (1998) 6:1127–1152.
  • •The evolution of 'chemical genetics'.
  • SAUSVILLE EA: Targeted toxins. In: Encyclopedia of Cancer (Vol. HI). Bertino J (Ed.), Academic Press, San Diego, USA (1997):1703–1714.
  • BORMAN S: Enediyne research continues apace. Chem. Eng. News (2000) (13 March):47–49.
  • ANONYMOUS: The Cancer Letter, Business & Regulator)/ Report (2000) 15:7.
  • LIU C, TADAYONI BM, BOURRET LA et al.: Eradication of large colon tumor xenografts by targeted delivery of maytansanoids. Proc. Nod Acad. Sci. USA (1996) 93:8618–8623.
  • VASEY PA, KAYE SB, MORRISON R et al: Phase I clinicaland pharmacokinetic study of PK1 [N-(2- hydroxy-propyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. (1999) 5:83–94.
  • JULYAN PJ, SEYMOUR LW, FERRY DR et al.: Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. j Con. Rel. (1999) 57:281–290.
  • MELTON RG, SHERWOOD RF: Antibody-enzyme conjugates for cancer therapy. J Natl. Can. Inst. (1996) 88:153–165.
  • •The theory and practice of 'ADEPT' applied to antitumour therapy.
  • HORAN AC: Actinomycetes. In: The Discovery of Natural Products with Therapeutic Potential. Gullo VP (Ed.), Butterworth-Heinemann, Boston, USA (19903–30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.